Skip to content
IP + Technology Law
Susan M. Janicki - Associate - Washington DC

Susan M. Janicki, Ph.D.

Associate
Washington DC
[email protected]
202-640-6400
vcard iconDownload vCard

Overview

Susan Janicki’s practice includes patent prosecution with an emphasis on biotechnology in the life sciences industries. Dr. Janicki received her Bachelor’s Degree in Biology from Tufts University. She received her Ph.D. in Human Genetics from the University of Maryland, Baltimore, and she completed a postdoctoral fellowship at Cold Spring Harbor Laboratory where she developed methods for studying chromatin and nuclear organization in living cells. Subsequently, Dr. Janicki ran an extramurally funded research laboratory at the Wistar Institute focused on understanding how mutations in chromatin regulatory proteins cause cancer.

Dr. Janicki attended Drexel University Thomas R. Kline School of Law, where she interned at the U.S. District Court for the District of Delaware with the Honorable Christopher J. Burke, United States Magistrate Judge.

Dr. Janicki worked as a summer associate in 2022 and joined the firm as an associate in 2023.

Extern Experience

Judicial Extern to the Honorable Christopher J. Burke, United States Magistrate Judge, United States Court for the District of Delaware, Spring 2022 Semester.

Teaching/Adjunct Professor Experience

Assistant Professor, Wistar Institute, April 2005 – December 2016

Associate Professor, Wister Institute, January 2014 – December 2016

Instructor, Rowan University, Department of Biological Sciences, January 2017 – June 2018

Education

  • Drexel University Thomas R. Kline School of Law (J.D., 2022), Rising Advocate Scholarship
  • University of Maryland, Baltimore (Ph.D. Human Genetics, 1999)
  • Tufts University (B.S. Biology and English, 1993)

Bar Admissions

  • District of Columbia Bar
  • U.S. Patent and Trademark Office

Recognition

Awards & Honors

Edward Mallinckrodt, Jr. Foundation Award, 2005-2008

Beckman Young Investigator Award, 2006-2009

Emerald Foundation Award, 2006-2008

V Foundation Scholar Award, 2007-2009

March of Dimes Basil O’Connor Starter Scholar Research Award, 2008-2010

News & Insights

Articles

Latest Updates and News

Blog - Biotechnology
Nov 2024
New Tool From EPA, FDA, and USDA Guides Developers of Genetically Modified Microorganisms Through Regulatory Landscape
On October 2, 2024, the U.S. Department of Agriculture (USDA), U.S. Environmental Protection Agency (EPA), and U.S. Food and Drug Administration (FDA) released a new web-based interactive tool on the Unified Website for Biotechnology Regulation for companies that develop microbial biotechnology products. The purpose of the tool is to help developers fulfill the regulatory requirements necessary to work with genetically modified microorganisms. The tool defines "genetic modification" as any technique that uses recombinant, synthesized, or amplified nucleic acids to modify or create a genome. “Microorganisms” include prokaryotes (e.g., bacteria and archaea), protists (e.g., amoebas), fungi (e.g., yeast, mold, mushrooms), green and red algae, and viruses or virus-like particles. Through a series of prompts, the tool provides users with information on regulatory requirements and the approval process across agencies. A built-in feedback function allows stakeholders to submit feedback directly to the agencies, which have expressed a commitment to continuing to improve the tool and expand its utility, scope and user base.
Blog - Biotechnology
Sep 2024
Senate Seeks to Reduce Biosimilar Prices by “Pruning” “Patent Thickets”
On July 10, the Senate unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S.150), which seeks to increase competition and lower drug prices by imposing limits on patent litigation related to biological products. The bill attempts to target “patent thickets” or the large patent portfolios companies create with significantly overlapping patent rights seen by lawmakers as obstacles to competitors entering the market.
Blog - Biotechnology
Jul 2024
WIPO Member States Adopt New Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge
On May 24, 2024, member states of the World Intellectual Property Organization (WIPO) adopted a new treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge that was over 20 years in the making. Genetic resources, which can include medicinal plants, agriculture crops and animal breeds, cannot themselves be claimed as intellectual property. However, inventions developed using genetic resources can be protected, usually through patents. The stated goals of the treaty include enhancing the efficacy, transparency, and quality of the patent system and preventing patents from being granted erroneously for inventions that are not novel or inventive with regard to genetic resources and traditional knowledge.
Blog - Biotechnology
Dec 2023
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
The Federal Trade Commission (FTC) issued a policy statement on September 14, 2023, stating that “[b]rand drug manufacturers may be harming generic competition through the improper listing of patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations, known as the ‘Orange Book.’” The FTC’s stated goal was to notify market participants of the FTC’s intent to scrutinize improper Orange Book listings to determine whether they constitute unfair methods of competition in violation of Section 5 of the Federal Trade Commission Act. On November 7, 2023, the FTC followed through on its warning by sending notice letters to more than 10 companies challenging the Orange Book listing of more than 100 patents covering products including specific asthma and other inhaler devices, Restasis multidose bottles, and epinephrine autoinjectors.